CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells

scientific article

CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2013PLoSO...860383K
P356DOI10.1371/JOURNAL.PONE.0060383
P932PMC publication ID3614906
P698PubMed publication ID23565238
P5875ResearchGate publication ID236129836

P50authorChoung-Soo KimQ56635696
P2093author name stringJe-Hwan Lee
Jene Choi
Jung Jin Hwang
Se Jin Jang
Seonggu Ro
Hyun Mi Kim
P2860cites workClinical and biological significance of GSK-3β inactivation in breast cancer-an immunohistochemical study.Q54656195
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cellsQ35900933
Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewalQ37080793
The role of glycogen synthase kinase-3beta in normal haematopoiesis, angiogenesis and leukaemiaQ37184977
Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinomaQ37481890
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.Q39937420
A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancerQ40075501
Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptorQ40111979
Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.Q40134202
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cellsQ40158471
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma researchQ40227151
Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcriptionQ40372631
Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cellsQ40444210
Wnt signaling controls the phosphorylation status of beta-catenin.Q42162259
Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrationsQ42791472
Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cellsQ46735228
Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damageQ24534352
GSK-3: tricks of the trade for a multi-tasking kinaseQ24624069
Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesisQ24655172
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulationQ24655658
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeuticsQ24685475
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activationQ28140761
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localizationQ28290083
Molecular cloning and expression of glycogen synthase kinase-3/factor AQ28569645
The phosphatidylinositol 3-Kinase AKT pathway in human cancerQ29547860
The glamour and gloom of glycogen synthase kinase-3Q29620533
Glycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53Q34338748
Glycogen synthase kinase 3: an emerging therapeutic targetQ34552674
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.Q35204486
GSK3 inhibitors: development and therapeutic potentialQ35790372
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectcell deathQ2383867
P304page(s)e60383
P577publication date2013-04-02
P1433published inPLOS OneQ564954
P1476titleCG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells
P478volume8

Reverse relations

cites work (P2860)
Q91592473Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling
Q93185115CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor
Q54302548Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth.
Q92290872GSK3-β Stimulates Claspin Degradation via β-TrCP Ubiquitin Ligase and Alters Cancer Cell Survival
Q35667570Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease
Q37640802Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.
Q64250238MicroRNA-143 is Associated With Pathological Complete Response and Regulates Multiple Signaling Proteins in Breast Cancer
Q39067484Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Q57107973Polyubiquitination inhibition of estrogen receptor alpha and its implications in breast cancer
Q28854594The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways
Q28551465Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway
Q47299786WNT Signaling in Cardiac and Vascular Disease.

Search more.